Peter E. Clark, MD, of the Vanderbilt-Ingram Cancer Center discusses the highlights of the 2015 NCCN Guidelines for bladder cancer in both non–muscle invasive and muscle-invasive disease.
Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.
Amy Cyr, MD, of the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, discusses advances made in the treatment of early-stage breast cancer: less radiation and a shorter course, the rising use of molecular profiling, and less invasive surgery and reduced amounts of surgery.
Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.
Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted treatments can and should be addressed.
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, discusses cardiac toxicities in cancer survivors, a new topic for the NCCN Survivorship Guidelines this year, and the need for more research on this important side effect, including prevention and surveillance.
